Agios Pharma stock rating downgraded by RBC Capital after mixed trial data
NegativeFinancial Markets

- RBC Capital has downgraded Agios Pharma's stock rating due to mixed results from recent clinical trials, indicating potential challenges for the company in achieving its objectives.
- This downgrade could negatively impact investor confidence and the company's market position, suggesting that Agios Pharma may need to address the concerns raised by the trial data to regain trust and improve its stock performance.
— via World Pulse Now AI Editorial System

